NCT03485235

Brief Summary

Effect of dilatation and curettage on the endometrial receptivity and pregnancy outcome in patients with recurrent implantation failure

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 26, 2018

Completed
5 days until next milestone

Study Start

First participant enrolled

March 31, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 2, 2018

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2019

Completed
Last Updated

January 28, 2020

Status Verified

January 1, 2020

Enrollment Period

1.6 years

First QC Date

March 26, 2018

Last Update Submit

January 26, 2020

Conditions

Embryo Implantation

Outcome Measures

Primary Outcomes (1)

  • Live Birth Rate

    9 months

Study Arms (2)

D&C

EXPERIMENTAL
Procedure: D&CProcedure: ICSI

No D&C

OTHER
Procedure: ICSI

Interventions

D&CPROCEDURE

Dilatation and curettage

D&C
ICSIPROCEDURE

Intra Cytoplasmic Sperm Injection

D&CNo D&C

Eligibility Criteria

Age25 Years - 35 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • All the patients had at least 3 failed trials of IVF-ET with day 5 fresh blastocyst transferred
  • At least 10 high-grade embryos were obtained in the previous trials
  • Level of AMH more than or equal 1.1 ng/ml.
  • Age: Less than or equal to 35 years

You may not qualify if:

  • Patients with uterine pathology e.g. myoma , Asherman syndrome, Septum ,adenomyosis
  • Hydrosalpinx
  • Endometriosis
  • patients with diagnosed autoimmune diseases affecting pregnancy e.g. S.L.E.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams University Maternity Hospital

Cairo, Egypt

Location

MeSH Terms

Interventions

Sperm Injections, Intracytoplasmic

Intervention Hierarchy (Ancestors)

Fertilization in VitroReproductive Techniques, AssistedReproductive TechniquesTherapeuticsInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 26, 2018

First Posted

April 2, 2018

Study Start

March 31, 2018

Primary Completion

November 1, 2019

Study Completion

December 10, 2019

Last Updated

January 28, 2020

Record last verified: 2020-01

Locations

EG(1)